ID   AMFR_HUMAN              Reviewed;         643 AA.
AC   Q9UKV5; P26442; Q8IZ70;
DT   19-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 2.
DT   28-JUN-2023, entry version 195.
DE   RecName: Full=E3 ubiquitin-protein ligase AMFR;
DE            EC=2.3.2.36 {ECO:0000269|PubMed:28604676, ECO:0000269|PubMed:31953408};
DE   AltName: Full=Autocrine motility factor receptor {ECO:0000303|PubMed:10456327};
DE            Short=AMF receptor {ECO:0000303|PubMed:10456327};
DE   AltName: Full=RING finger protein 45;
DE   AltName: Full=gp78 {ECO:0000303|PubMed:11724934};
GN   Name=AMFR {ECO:0000303|PubMed:10456327, ECO:0000312|HGNC:HGNC:463};
GN   Synonyms=RNF45 {ECO:0000312|HGNC:HGNC:463};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAD56722.1};
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=10456327; DOI=10.1016/s0014-5793(99)00966-7;
RA   Shimizu K., Tani M., Watanabe H., Nagamachi Y., Niinaka Y., Shiroishi T.,
RA   Ohwada S., Raz A., Yokota J.;
RT   "The autocrine motility factor receptor gene encodes a novel type of seven
RT   transmembrane protein.";
RL   FEBS Lett. 456:295-300(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 358-643.
RC   TISSUE=Placenta;
RX   PubMed=7626106; DOI=10.1006/bbrc.1995.2031;
RA   Huang B., Xie Y., Raz A.;
RT   "Identification of an upstream region that controls the transcription of
RT   the human autocrine motility factor receptor.";
RL   Biochem. Biophys. Res. Commun. 212:727-742(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 520-643.
RX   PubMed=1649192; DOI=10.1016/s0021-9258(18)98859-9;
RA   Watanabe H., Carmi P., Hogan V., Raz T., Silletti S., Nabi I.R., Raz A.;
RT   "Purification of human tumor cell autocrine motility factor and molecular
RT   cloning of its receptor.";
RL   J. Biol. Chem. 266:13442-13448(1991).
RN   [5]
RP   FUNCTION AS A UBIQUITIN LIGASE, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   UBE2G2.
RX   PubMed=11724934; DOI=10.1073/pnas.251401598;
RA   Fang S., Ferrone M., Yang C., Jensen J.P., Tiwari S., Weissman A.M.;
RT   "The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein
RT   ligase implicated in degradation from the endoplasmic reticulum.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:14422-14427(2001).
RN   [6]
RP   FUNCTION IN UBIQUITINATION OF APOB.
RX   PubMed=12670940; DOI=10.1074/jbc.m302683200;
RA   Liang J.S., Kim T., Fang S., Yamaguchi J., Weissman A.M., Fisher E.A.,
RA   Ginsberg H.N.;
RT   "Overexpression of the tumor autocrine motility factor receptor, gp78, a
RT   ubiquitin protein ligase (E3), results in increased ubiquitinylation and
RT   decreased secretion of apolipoprotein B100 in Hep G2 cells.";
RL   J. Biol. Chem. 278:23984-23988(2003).
RN   [7]
RP   INTERACTION WITH INSIG1 AND VCP, FUNCTION, AND MUTAGENESIS OF CYS-356.
RX   PubMed=16168377; DOI=10.1016/j.molcel.2005.08.009;
RA   Song B.L., Sever N., DeBose-Boyd R.A.;
RT   "Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and
RT   couples sterol-regulated ubiquitination to degradation of HMG CoA
RT   reductase.";
RL   Mol. Cell 19:829-840(2005).
RN   [8]
RP   INTERACTION WITH DERL1 AND VCP.
RX   PubMed=16186510; DOI=10.1073/pnas.0505006102;
RA   Ye Y., Shibata Y., Kikkert M., van Voorden S., Wiertz E., Rapoport T.A.;
RT   "Recruitment of the p97 ATPase and ubiquitin ligases to the site of
RT   retrotranslocation at the endoplasmic reticulum membrane.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14132-14138(2005).
RN   [9]
RP   FUNCTION.
RX   PubMed=17043353; DOI=10.1074/jbc.m608999200;
RA   Lee J.N., Song B., DeBose-Boyd R.A., Ye J.;
RT   "Sterol-regulated degradation of Insig-1 mediated by the membrane-bound
RT   ubiquitin ligase gp78.";
RL   J. Biol. Chem. 281:39308-39315(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-516, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   FUNCTION.
RX   PubMed=19103148; DOI=10.1016/j.abb.2008.12.001;
RA   Pabarcus M.K., Hoe N., Sadeghi S., Patterson C., Wiertz E., Correia M.A.;
RT   "CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor
RT   receptor, AMFR) and CHIP E3 ligases.";
RL   Arch. Biochem. Biophys. 483:66-74(2009).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH BAG6.
RX   PubMed=21636303; DOI=10.1016/j.molcel.2011.05.010;
RA   Wang Q., Liu Y., Soetandyo N., Baek K., Hegde R., Ye Y.;
RT   "A ubiquitin ligase-associated chaperone holdase maintains polypeptides in
RT   soluble states for proteasome degradation.";
RL   Mol. Cell 42:758-770(2011).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH INSIG1.
RX   PubMed=22143767; DOI=10.1073/pnas.1112831108;
RA   Jo Y., Lee P.C., Sguigna P.V., DeBose-Boyd R.A.;
RT   "Sterol-induced degradation of HMG CoA reductase depends on interplay of
RT   two Insigs and two ubiquitin ligases, gp78 and Trc8.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:20503-20508(2011).
RN   [14]
RP   SUBCELLULAR LOCATION, PALMITOYLATION, AND MUTAGENESIS OF 341-CYS--CYS-344;
RP   CYS-356; CYS-364 AND 375-CYS--CYS-378.
RX   PubMed=22728137; DOI=10.1016/j.febslet.2012.06.011;
RA   Fairbank M., Huang K., El-Husseini A., Nabi I.R.;
RT   "RING finger palmitoylation of the endoplasmic reticulum Gp78 E3 ubiquitin
RT   ligase.";
RL   FEBS Lett. 586:2488-2493(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-542, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH AUP1; RNF139 AND UBE2G2.
RX   PubMed=23223569; DOI=10.1091/mbc.e12-07-0564;
RA   Jo Y., Hartman I.Z., DeBose-Boyd R.A.;
RT   "Ancient ubiquitous protein-1 mediates sterol-induced ubiquitination of 3-
RT   hydroxy-3-methylglutaryl CoA reductase in lipid droplet-associated
RT   endoplasmic reticulum membranes.";
RL   Mol. Biol. Cell 24:169-183(2013).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH USP13.
RX   PubMed=24424410; DOI=10.7554/elife.01369;
RA   Liu Y., Soetandyo N., Lee J.G., Liu L., Xu Y., Clemons W.M. Jr., Ye Y.;
RT   "USP13 antagonizes gp78 to maintain functionality of a chaperone in ER-
RT   associated degradation.";
RL   Elife 3:E01369-E01369(2014).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-523, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   INTERACTION WITH C18ORF32.
RX   PubMed=29275994; DOI=10.1016/j.devcel.2017.11.020;
RA   Bersuker K., Peterson C.W.H., To M., Sahl S.J., Savikhin V., Grossman E.A.,
RA   Nomura D.K., Olzmann J.A.;
RT   "A Proximity Labeling Strategy Provides Insights into the Composition and
RT   Dynamics of Lipid Droplet Proteomes.";
RL   Dev. Cell 44:97-112(2018).
RN   [20]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=28604676; DOI=10.1038/ncb3551;
RA   Wang Y.J., Bian Y., Luo J., Lu M., Xiong Y., Guo S.Y., Yin H.Y., Lin X.,
RA   Li Q., Chang C.C.Y., Chang T.Y., Li B.L., Song B.L.;
RT   "Cholesterol and fatty acids regulate cysteine ubiquitylation of ACAT2
RT   through competitive oxidation.";
RL   Nat. Cell Biol. 19:808-819(2017).
RN   [21]
RP   ERRATUM OF PUBMED:28604676.
RX   PubMed=29184177; DOI=10.1038/ncb3651;
RA   Wang Y.J., Bian Y., Luo J., Lu M., Xiong Y., Guo S.Y., Yong H., Lin X.,
RA   Li Q., Chang C.C.Y., Chang T.Y., Li B.L., Song B.L.;
RT   "Corrigendum: Cholesterol and fatty acids regulate cysteine ubiquitylation
RT   of ACAT2 through competitive oxidation.";
RL   Nat. Cell Biol. 19:1441-1441(2017).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH LMBR1L.
RX   PubMed=31073040; DOI=10.1126/science.aau0812;
RA   Choi J.H., Zhong X., McAlpine W., Liao T.C., Zhang D., Fang B., Russell J.,
RA   Ludwig S., Nair-Gill E., Zhang Z., Wang K.W., Misawa T., Zhan X., Choi M.,
RA   Wang T., Li X., Tang M., Sun Q., Yu L., Murray A.R., Moresco E.M.Y.,
RA   Beutler B.;
RT   "LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling.";
RL   Science 364:0-0(2019).
RN   [23]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=31953408; DOI=10.1038/s41467-019-14231-w;
RA   Zhou Z.S., Li M.X., Liu J., Jiao H., Xia J.M., Shi X.J., Zhao H., Chu L.,
RA   Liu J., Qi W., Luo J., Song B.L.;
RT   "Competitive oxidation and ubiquitylation on the evolutionarily conserved
RT   cysteine confer tissue-specific stabilization of Insig-2.";
RL   Nat. Commun. 11:379-379(2020).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH STAPHYLOCOCCUS AUREUS HLGB
RP   (MICROBIAL INFECTION), AND MUTAGENESIS OF ASP-346 AND ARG-379.
RX   PubMed=36593296; DOI=10.1038/s41564-022-01278-7;
RA   Sun L., Zhang H., Zhang H., Lou X., Wang Z., Wu Y., Yang X., Chen D.,
RA   Guo B., Zhang A., Qian F.;
RT   "Staphylococcal virulence factor HlgB targets the endoplasmic-reticulum-
RT   resident E3 ubiquitin ligase AMFR to promote pneumonia.";
RL   Nat. Microbiol. 8:107-120(2023).
RN   [25]
RP   STRUCTURE BY NMR OF 452-502.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RSGI RUH-076, a human CUE domain.";
RL   Submitted (SEP-2007) to the PDB data bank.
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 622-640 IN COMPLEX WITH VCP, AND
RP   VIM MOTIF.
RX   PubMed=21914798; DOI=10.1074/jbc.m111.274506;
RA   Hanzelmann P., Schindelin H.;
RT   "The structural and functional basis of the p97/valosin-containing protein
RT   (VCP)-interacting motif (VIM): mutually exclusive binding of cofactors to
RT   the N-terminal domain of p97.";
RL   J. Biol. Chem. 286:38679-38690(2011).
RN   [27]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-605.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that mediates the
CC       polyubiquitination of lysine and cysteine residues on target proteins,
CC       such as CD3D, CYP3A4, CFTR, INSIG1, SOAT2/ACAT2 and APOB for
CC       proteasomal degradation (PubMed:10456327, PubMed:11724934,
CC       PubMed:12670940, PubMed:19103148, PubMed:24424410, PubMed:28604676).
CC       Component of a VCP/p97-AMFR/gp78 complex that participates in the final
CC       step of endoplasmic reticulum-associated degradation (ERAD)
CC       (PubMed:10456327, PubMed:11724934, PubMed:19103148, PubMed:24424410).
CC       The VCP/p97-AMFR/gp78 complex is involved in the sterol-accelerated
CC       ERAD degradation of HMGCR through binding to the HMGCR-INSIG1 complex
CC       at the ER membrane (PubMed:16168377, PubMed:22143767). In addition,
CC       interaction of AMFR with AUP1 facilitates interaction of AMFR with
CC       ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase RNF139,
CC       leading to sterol-induced HMGCR ubiquitination (PubMed:23223569). The
CC       ubiquitinated HMGCR is then released from the ER into the cytosol for
CC       subsequent destruction (PubMed:16168377, PubMed:22143767,
CC       PubMed:23223569). In addition to ubiquitination on lysine residues,
CC       catalyzes ubiquitination on cysteine residues: together with INSIG1,
CC       mediates polyubiquitination of SOAT2/ACAT2 at 'Cys-277', leading to its
CC       degradation when the lipid levels are low (PubMed:28604676). Catalyzes
CC       ubiquitination and subsequent degradation of INSIG1 when cells are
CC       depleted of sterols (PubMed:17043353). Mediates polyubiquitination of
CC       INSIG2 at 'Cys-215' in some tissues, leading to its degradation
CC       (PubMed:31953408). Also regulates ERAD through the ubiquitination of
CC       UBL4A a component of the BAG6/BAT3 complex (PubMed:21636303). Also acts
CC       as a scaffold protein to assemble a complex that couples
CC       ubiquitination, retranslocation and deglycosylation (PubMed:21636303).
CC       Mediates tumor invasion and metastasis as a receptor for the
CC       GPI/autocrine motility factor (PubMed:10456327). In association with
CC       LMBR1L and UBAC2, negatively regulates the canonical Wnt signaling
CC       pathway in the lymphocytes by promoting the ubiquitin-mediated
CC       degradation of CTNNB1 and Wnt receptors FZD6 and LRP6
CC       (PubMed:31073040). Regulates NF-kappa-B and MAPK signaling pathways by
CC       mediating 'Lys-27'-linked polyubiquitination of TAB3 and promoting
CC       subsequent TAK1/MAP3K7 activation (PubMed:36593296).
CC       {ECO:0000269|PubMed:10456327, ECO:0000269|PubMed:11724934,
CC       ECO:0000269|PubMed:12670940, ECO:0000269|PubMed:16168377,
CC       ECO:0000269|PubMed:17043353, ECO:0000269|PubMed:19103148,
CC       ECO:0000269|PubMed:21636303, ECO:0000269|PubMed:22143767,
CC       ECO:0000269|PubMed:23223569, ECO:0000269|PubMed:24424410,
CC       ECO:0000269|PubMed:28604676, ECO:0000269|PubMed:31073040,
CC       ECO:0000269|PubMed:31953408, ECO:0000269|PubMed:36593296}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[E2 ubiquitin-conjugating enzyme]-S-ubiquitinyl-L-cysteine +
CC         [acceptor protein]-L-cysteine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + [acceptor protein]-S-ubiquitinyl-L-cysteine.; EC=2.3.2.36;
CC         Evidence={ECO:0000269|PubMed:28604676, ECO:0000269|PubMed:31953408};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:11724934, ECO:0000269|PubMed:16168377}.
CC   -!- SUBUNIT: Interacts with RNF5 (By similarity). Also forms an ERAD
CC       complex containing VCP/p97, NGLY1; PSMC1; SAKS1 and RAD23B required for
CC       coupling retrotranslocation, ubiquitination and deglycosylation (By
CC       similarity). Interacts with DERL1 (PubMed:16186510). Interacts (through
CC       a region distinct from the RING finger) with UBE2G2/UBC7
CC       (PubMed:11724934). Component of the VCP/p97-AMFR/gp78 complex that
CC       enhances VCP/p97 binding to polyubiquitinated proteins for their
CC       degradation by the endoplasmic reticulum-associated degradation (ERAD)
CC       pathway (By similarity). Interacts (via the VIM) with VCP/p97
CC       (PubMed:16168377, PubMed:16186510). Interacts (via its membrane domain)
CC       with INSIG1; the interaction initiates the sterol-mediated
CC       ubiquitination and degradation of HMGCR by the ERAD pathway
CC       (PubMed:16168377, PubMed:22143767). Interacts with AUP1, UBE2G2 and
CC       RNF139/TRC8; interaction with AUP1 facilitates interaction of AMFR with
CC       ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase RNF139,
CC       leading to sterol-induced ubiquitination of HMGCR and its subsequent
CC       proteasomal degradation (PubMed:23223569). Interacts with BAG6
CC       (PubMed:21636303). Interacts with USP13 (via UBA 2 domain); the
CC       interaction is direct (PubMed:24424410). Interacts with LMBR1L
CC       (PubMed:31073040). Interacts with UBAC2 and CTNNB1 (By similarity).
CC       Interacts with C18orf32 (PubMed:29275994).
CC       {ECO:0000250|UniProtKB:Q9R049, ECO:0000269|PubMed:11724934,
CC       ECO:0000269|PubMed:16168377, ECO:0000269|PubMed:16186510,
CC       ECO:0000269|PubMed:21636303, ECO:0000269|PubMed:21914798,
CC       ECO:0000269|PubMed:22143767, ECO:0000269|PubMed:23223569,
CC       ECO:0000269|PubMed:24424410, ECO:0000269|PubMed:29275994,
CC       ECO:0000305|PubMed:31073040}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Staphylococcus aureus
CC       HIgB; this interaction regulates AMFR-mediated inflammation by
CC       promoting TAB3 ubiquitination to promote TAB3-TAK1 complex formation.
CC       {ECO:0000269|PubMed:36593296}.
CC   -!- INTERACTION:
CC       Q9UKV5; Q9UKV5: AMFR; NbExp=11; IntAct=EBI-1046367, EBI-1046367;
CC       Q9UKV5; O75477: ERLIN1; NbExp=2; IntAct=EBI-1046367, EBI-359299;
CC       Q9UKV5; O94905: ERLIN2; NbExp=10; IntAct=EBI-1046367, EBI-4400770;
CC       Q9UKV5; O15503: INSIG1; NbExp=2; IntAct=EBI-1046367, EBI-6252425;
CC       Q9UKV5; Q9BVT8: TMUB1; NbExp=2; IntAct=EBI-1046367, EBI-11425701;
CC       Q9UKV5; P60604: UBE2G2; NbExp=21; IntAct=EBI-1046367, EBI-1051028;
CC       Q9UKV5; P55072: VCP; NbExp=12; IntAct=EBI-1046367, EBI-355164;
CC       Q9UKV5; P60605: Ube2g2; Xeno; NbExp=10; IntAct=EBI-1046367, EBI-9108745;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:11724934, ECO:0000269|PubMed:22728137,
CC       ECO:0000269|PubMed:36593296}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:11724934}. Note=Palmitoylation promotes
CC       localization to the peripheral endoplasmic reticulum.
CC       {ECO:0000269|PubMed:22728137}.
CC   -!- DOMAIN: The CUE domain is required for recognition of misfolded
CC       proteins such as mutant CFTR. {ECO:0000250|UniProtKB:Q9R049}.
CC   -!- DOMAIN: The VCP/p97-interacting motif (VIM) is sufficient for binding
CC       VCP/p97 to form a complex capable of transferring VCP/p97 from the
CC       cytosol to microsomes. {ECO:0000269|PubMed:21914798}.
CC   -!- PTM: Palmitoylation of the RING-type zing finger by ZDHHC6 promotes
CC       localization to the peripheral endoplasmic reticulum.
CC       {ECO:0000269|PubMed:22728137}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA36671.1; Type=Miscellaneous discrepancy; Note=Several sequencing errors.; Evidence={ECO:0000305};
CC       Sequence=AAA79362.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/627/AMFR";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF124145; AAD56722.1; -; mRNA.
DR   EMBL; BC069197; AAH69197.1; -; mRNA.
DR   EMBL; L35233; AAA79362.1; ALT_FRAME; mRNA.
DR   EMBL; M63175; AAA36671.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS10758.1; -.
DR   PIR; A39877; A39877.
DR   RefSeq; NP_001135.3; NM_001144.5.
DR   RefSeq; NP_001310441.1; NM_001323512.1.
DR   PDB; 2EJS; NMR; -; A=452-502.
DR   PDB; 2LVN; NMR; -; C=453-504.
DR   PDB; 2LVO; NMR; -; C=453-504.
DR   PDB; 2LVP; NMR; -; C=453-504.
DR   PDB; 2LVQ; NMR; -; D=453-504.
DR   PDB; 2LXH; NMR; -; C=313-393.
DR   PDB; 2LXP; NMR; -; B=574-600, C=327-384.
DR   PDB; 3FSH; X-ray; 2.76 A; C=574-601.
DR   PDB; 3H8K; X-ray; 1.80 A; B=573-600.
DR   PDB; 3TIW; X-ray; 1.80 A; C/D=622-640.
DR   PDB; 4G3O; X-ray; 1.60 A; A=456-498.
DR   PDB; 4LAD; X-ray; 2.30 A; B=313-393, B=574-600.
DR   PDBsum; 2EJS; -.
DR   PDBsum; 2LVN; -.
DR   PDBsum; 2LVO; -.
DR   PDBsum; 2LVP; -.
DR   PDBsum; 2LVQ; -.
DR   PDBsum; 2LXH; -.
DR   PDBsum; 2LXP; -.
DR   PDBsum; 3FSH; -.
DR   PDBsum; 3H8K; -.
DR   PDBsum; 3TIW; -.
DR   PDBsum; 4G3O; -.
DR   PDBsum; 4LAD; -.
DR   AlphaFoldDB; Q9UKV5; -.
DR   BMRB; Q9UKV5; -.
DR   SMR; Q9UKV5; -.
DR   BioGRID; 106764; 252.
DR   CORUM; Q9UKV5; -.
DR   DIP; DIP-29060N; -.
DR   IntAct; Q9UKV5; 73.
DR   MINT; Q9UKV5; -.
DR   STRING; 9606.ENSP00000290649; -.
DR   TCDB; 8.A.183.1.1; the rela-associated inhibitor (rai) family.
DR   iPTMnet; Q9UKV5; -.
DR   PhosphoSitePlus; Q9UKV5; -.
DR   SwissPalm; Q9UKV5; -.
DR   BioMuta; AMFR; -.
DR   DMDM; 34922250; -.
DR   EPD; Q9UKV5; -.
DR   jPOST; Q9UKV5; -.
DR   MassIVE; Q9UKV5; -.
DR   MaxQB; Q9UKV5; -.
DR   PaxDb; Q9UKV5; -.
DR   PeptideAtlas; Q9UKV5; -.
DR   ProteomicsDB; 54350; -.
DR   ProteomicsDB; 84893; -.
DR   Antibodypedia; 14770; 325 antibodies from 31 providers.
DR   DNASU; 267; -.
DR   Ensembl; ENST00000290649.10; ENSP00000290649.5; ENSG00000159461.15.
DR   GeneID; 267; -.
DR   KEGG; hsa:267; -.
DR   MANE-Select; ENST00000290649.10; ENSP00000290649.5; NM_001144.6; NP_001135.3.
DR   UCSC; uc002eiy.4; human.
DR   AGR; HGNC:463; -.
DR   CTD; 267; -.
DR   DisGeNET; 267; -.
DR   GeneCards; AMFR; -.
DR   HGNC; HGNC:463; AMFR.
DR   HPA; ENSG00000159461; Low tissue specificity.
DR   MIM; 603243; gene.
DR   neXtProt; NX_Q9UKV5; -.
DR   OpenTargets; ENSG00000159461; -.
DR   PharmGKB; PA24768; -.
DR   VEuPathDB; HostDB:ENSG00000159461; -.
DR   eggNOG; KOG0802; Eukaryota.
DR   GeneTree; ENSGT00940000156482; -.
DR   HOGENOM; CLU_015061_0_0_1; -.
DR   InParanoid; Q9UKV5; -.
DR   OMA; LHHVHML; -.
DR   OrthoDB; 2912447at2759; -.
DR   PhylomeDB; Q9UKV5; -.
DR   TreeFam; TF320052; -.
DR   BRENDA; 2.3.2.27; 2681.
DR   PathwayCommons; Q9UKV5; -.
DR   Reactome; R-HSA-532668; N-glycan trimming in the ER and Calnexin/Calreticulin cycle.
DR   Reactome; R-HSA-901032; ER Quality Control Compartment (ERQC).
DR   SignaLink; Q9UKV5; -.
DR   SIGNOR; Q9UKV5; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 267; 30 hits in 1191 CRISPR screens.
DR   ChiTaRS; AMFR; human.
DR   EvolutionaryTrace; Q9UKV5; -.
DR   GeneWiki; AMFR; -.
DR   GenomeRNAi; 267; -.
DR   Pharos; Q9UKV5; Tbio.
DR   PRO; PR:Q9UKV5; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q9UKV5; protein.
DR   Bgee; ENSG00000159461; Expressed in stromal cell of endometrium and 198 other tissues.
DR   ExpressionAtlas; Q9UKV5; baseline and differential.
DR   Genevisible; Q9UKV5; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0036513; C:Derlin-1 retrotranslocation complex; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0044322; C:endoplasmic reticulum quality control compartment; IEA:GOC.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0000151; C:ubiquitin ligase complex; IBA:GO_Central.
DR   GO; GO:1904288; F:BAT3 complex binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0038023; F:signaling receptor activity; IPI:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IEA:InterPro.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0034450; F:ubiquitin-ubiquitin ligase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:1904380; P:endoplasmic reticulum mannose trimming; TAS:Reactome.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IMP:UniProtKB.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; IDA:UniProt.
DR   GO; GO:0032092; P:positive regulation of protein binding; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0044314; P:protein K27-linked ubiquitination; IDA:UniProt.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:2000638; P:regulation of SREBP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0030433; P:ubiquitin-dependent ERAD pathway; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   CDD; cd14421; CUE_AMFR; 1.
DR   CDD; cd16455; RING-H2_AMFR; 1.
DR   Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   IDEAL; IID00226; -.
DR   InterPro; IPR040675; AMFR_Ube2g2-bd.
DR   InterPro; IPR003892; CUE.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR15067:SF5; E3 UBIQUITIN-PROTEIN LIGASE AMFR; 1.
DR   PANTHER; PTHR15067; E3 UBIQUITIN-PROTEIN LIGASE RNF8; 1.
DR   Pfam; PF02845; CUE; 1.
DR   Pfam; PF18442; G2BR; 1.
DR   Pfam; PF13639; zf-RING_2; 1.
DR   SMART; SM00546; CUE; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   PROSITE; PS51140; CUE; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Endoplasmic reticulum; Lipoprotein; Membrane; Metal-binding;
KW   Palmitate; Phosphoprotein; Receptor; Reference proteome; Transferase;
KW   Transmembrane; Transmembrane helix; Ubl conjugation pathway;
KW   Wnt signaling pathway; Zinc; Zinc-finger.
FT   CHAIN           1..643
FT                   /note="E3 ubiquitin-protein ligase AMFR"
FT                   /id="PRO_0000064579"
FT   TRANSMEM        82..102
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        122..142
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        145..165
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        186..206
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        215..235
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        276..296
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        429..449
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          456..498
FT                   /note="CUE"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00468"
FT   ZN_FING         341..379
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          39..67
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          504..579
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          596..624
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          622..640
FT                   /note="VCP/p97-interacting motif (VIM)"
FT                   /evidence="ECO:0000269|PubMed:21914798"
FT   COMPBIAS        504..521
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        561..579
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         516
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         542
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         605
FT                   /note="D -> V (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs373191257)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035790"
FT   MUTAGEN         341..344
FT                   /note="CAIC->AAIA: Decreased palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:22728137"
FT   MUTAGEN         346
FT                   /note="D->A: Abolished binding to TAB3."
FT                   /evidence="ECO:0000269|PubMed:36593296"
FT   MUTAGEN         356
FT                   /note="C->A: Decreased palmitoylation. No degradation of
FT                   HMGCR."
FT                   /evidence="ECO:0000269|PubMed:16168377,
FT                   ECO:0000269|PubMed:22728137"
FT   MUTAGEN         364
FT                   /note="C->A: Decreased palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:22728137"
FT   MUTAGEN         375..378
FT                   /note="CPTC->APTA: Decreased palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:22728137"
FT   MUTAGEN         379
FT                   /note="R->A: Abolished binding to TAB3."
FT                   /evidence="ECO:0000269|PubMed:36593296"
FT   CONFLICT        406
FT                   /note="V -> D (in Ref. 3; AAA79362)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        491
FT                   /note="D -> V (in Ref. 3; AAA79362)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        500
FT                   /note="V -> L (in Ref. 3; AAA79362)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        614
FT                   /note="S -> L (in Ref. 1; AAD56722)"
FT                   /evidence="ECO:0000305"
FT   HELIX           332..337
FT                   /evidence="ECO:0007829|PDB:2LXH"
FT   STRAND          342..344
FT                   /evidence="ECO:0007829|PDB:4LAD"
FT   STRAND          351..353
FT                   /evidence="ECO:0007829|PDB:4LAD"
FT   STRAND          355..357
FT                   /evidence="ECO:0007829|PDB:2LXH"
FT   STRAND          359..361
FT                   /evidence="ECO:0007829|PDB:4LAD"
FT   HELIX           362..369
FT                   /evidence="ECO:0007829|PDB:4LAD"
FT   STRAND          376..378
FT                   /evidence="ECO:0007829|PDB:4LAD"
FT   HELIX           456..467
FT                   /evidence="ECO:0007829|PDB:4G3O"
FT   HELIX           473..483
FT                   /evidence="ECO:0007829|PDB:4G3O"
FT   HELIX           486..494
FT                   /evidence="ECO:0007829|PDB:4G3O"
FT   HELIX           575..599
FT                   /evidence="ECO:0007829|PDB:3H8K"
FT   HELIX           625..637
FT                   /evidence="ECO:0007829|PDB:3TIW"
SQ   SEQUENCE   643 AA;  72996 MW;  8782324609C0E62A CRC64;
     MPLLFLERFP WPSLRTYTGL SGLALLGTII SAYRALSQPE AGPGEPDQLT ASLQPEPPAP
     ARPSAGGPRA RDVAQYLLSD SLFVWVLVNT ACCVLMLVAK LIQCIVFGPL RVSERQHLKD
     KFWNFIFYKF IFIFGVLNVQ TVEEVVMWCL WFAGLVFLHL MVQLCKDRFE YLSFSPTTPM
     SSHGRVLSLL VAMLLSCCGL AAVCSITGYT HGMHTLAFMA AESLLVTVRT AHVILRYVIH
     LWDLNHEGTW EGKGTYVYYT DFVMELTLLS LDLMHHIHML LFGNIWLSMA SLVIFMQLRY
     LFHEVQRRIR RHKNYLRVVG NMEARFAVAT PEELAVNNDD CAICWDSMQA ARKLPCGHLF
     HNSCLRSWLE QDTSCPTCRM SLNIADNNRV REEHQGENLD ENLVPVAAAE GRPRLNQHNH
     FFHFDGSRIA SWLPSFSVEV MHTTNILGIT QASNSQLNAM AHQIQEMFPQ VPYHLVLQDL
     QLTRSVEITT DNILEGRIQV PFPTQRSDSI RPALNSPVER PSSDQEEGET SAQTERVPLD
     LSPRLEETLD FGEVEVEPSE VEDFEARGSR FSKSADERQR MLVQRKDELL QQARKRFLNK
     SSEDDAASES FLPSEGASSD PVTLRRRMLA AAAERRLQKQ QTS
//
